S-1/A: BriaCell Therapeutics Files S-1/A for Public Offering Amid Promising Clinical Trial Data for Cancer Immunotherapies

BriaCell Therapeutics Corp. has filed an S-1/A registration statement for a public offering of up to 6,825,938 common and pre-funded units, while reporting strong clinical data for its Bria-IMT and Bria-OTS immunotherapies in metastatic breast cancer.

Summary

• BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer.
• The company is advancing its Bria-IMT targeted immunotherapy in combination with an immune checkpoint inhibitor (Retifanlimab) in a pivotal Phase 3 study for metastatic breast cancer, which has received FDA Fast Track Designation.
• A Phase 1/2 study (NCT06471673) is evaluating Bria-OTS, a personalized next-generation immunotherapy, alone and in combination with tislelizumab for metastatic breast cancer.
• Preclinical development is underway for Bria-OTS+, an enhanced version of Bria-OTS, and Bria-PROS+, a prostate cancer immunotherapy, with Bria-PROS+ having entered GMP manufacturing.
• Recent clinical data for Bria-IMT showed a 71% intracranial objective response rate (iORR) in patients with CNS metastases, and a median progression-free survival (PFS) of 3.5 months in heavily pre-treated metastatic breast cancer patients, comparable to or better than other studies.
• The Bria-IMT regimen demonstrated a clinical benefit rate (CBR) of 56% in evaluable patients across all breast cancer subtypes.
• Updated overall survival (OS) data for Bria-IMT in Phase 2 patients treated with the Phase 3 formulation showed a median OS of 13.4 months (15.6 months for those treated since 2022), which is approximately double that reported for similar patients in the literature (5.9-9.8 months).
• For TNBC patients, Bria-IMT plus CPI showed a median OS of 13.9 months, compared to 11.8 months for TRODELVY and 6.9 months for single-agent chemotherapy.
• For HR+ MBC patients, Bria-IMT plus CPI showed a median OS of 17.3 months, exceeding TRODELVY's 14.4 months and single-agent chemotherapy's 11.2 months.
• A patient treated with Bria-OTS monotherapy achieved 100% resolution of lung metastasis, confirmed at 4 months follow-up, and remained on study with stable disease elsewhere.
• The Data Safety Monitoring Board (DSMB) completed its first safety review of the pivotal Phase 3 study for Bria-IMT, recommending continuation with no safety concerns.
• The Phase 3 study has consented over 100 and enrolled over 75 patients, with anticipated completion of enrollment in late 2025 or early 2026, and top-line data as early as H1-2026.
• The company is offering up to 6,825,938 common units (one common share + one warrant) and/or pre-funded units (one pre-funded warrant + one warrant) at an assumed public offering price of $2.93 per common unit.
• Each warrant will entitle the holder to purchase one common share at an exercise price of $3.6625, expiring five years from issuance. Pre-funded warrants have an exercise price of $0.001 and do not expire prior to exercise.
• The offering is on a best-efforts basis with no minimum amount, and estimated net proceeds, assuming all securities are sold, are approximately $18.04 million.
• As of July 8, 2025, there are 6,776,092 common shares outstanding. After the offering, this could increase to 13,602,030 common shares, assuming no sales of Pre-Funded Units and no exercise of the Warrants.
• The company's net tangible book value as of April 30, 2025, was approximately $11.7 million ($1.73 per share), with an immediate dilution of $0.74 per share for new investors based on the assumed offering price.
• The company completed a 1-for-15 common share consolidation effective January 24, 2025, to comply with Nasdaq listing requirements.
• BriaPro Therapeutics Corp., a majority-owned subsidiary, is developing novel, high-affinity anti-B7-H3 antibodies for multiple cancer indications and plans to incorporate them into its Bria-TILsRx platform.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial data for BriaCell's immunotherapies, showing superior or comparable efficacy to existing treatments in challenging cancer populations, alongside a favorable safety profile. This strong clinical progress significantly de-risks the company's pipeline. While the company continues to incur losses and raise capital, the clinical advancements provide a strong basis for future value creation and investor confidence.

Positives

• Bria-IMT regimen achieved a 71% intracranial objective response rate (iORR) in patients with CNS metastases, addressing a significant unmet medical need.
• Median progression-free survival (PFS) of 3.5 months in heavily pre-treated patients is comparable to or better than similar studies with fewer prior treatments.
• Bria-IMT showed a clinical benefit rate (CBR) of 56% across all breast cancer subtypes, including 63% in HR+/HER2-, 100% in HER2+, and 66% in HR-/HER2 low subtypes.
• Median overall survival (OS) of 13.4 months (15.6 months for those treated since 2022) for Bria-IMT Phase 2 patients is approximately double that of comparable patients in the literature (5.9-9.8 months).
• Bria-IMT demonstrated superior median OS in TNBC (13.9 months vs. 11.8 months for TRODELVY) and HR+ MBC (17.3 months vs. 14.4 months for TRODELVY).
• Bria-OTS monotherapy resulted in 100% confirmed resolution of lung metastasis in a patient, supporting its personalized off-the-shelf approach.
• The Bria-IMT regimen has a favorable tolerability and safety profile, with no interstitial lung disease (ILD) incidents and no treatment-related discontinuations reported.
• The Data Safety Monitoring Board (DSMB) recommended continuation of the pivotal Phase 3 study for Bria-IMT, citing no safety concerns.
• FDA Fast Track Designation for Bria-IMT is intended to accelerate the review process for novel treatments addressing unmet medical needs.
• FDA authorized an Expanded Access Policy (EAP) for Bria-IMT, providing access to metastatic breast cancer patients beyond the clinical trial scope.
• Pre-IND meeting with FDA for Bria-PROS+ in prostate cancer did not require animal toxicology and pharmacokinetic studies, clarifying its development pathway.
• Identification of potential predictive biomarkers (DTH and NLR) for treatment response in Phase 3 patients could lead to better patient outcomes.
• The company regained compliance with Nasdaq's minimum bid price and shareholders' equity requirements.

Negatives

• The company reported a net loss of $(18,392,033) for the nine months ended April 30, 2025, indicating ongoing significant operating losses.
• Investors in the current offering will experience immediate and substantial dilution of $0.74 per share in the book value of their investment.
• The company has a history of significant net losses, with $(4,931,548) for the year ended July 31, 2024, and $(20,302,394) for the year ended July 31, 2023.
• There is no established public trading market for the Warrants and Pre-Funded Warrants being offered, limiting their liquidity.
• The offering is on a best-efforts basis with no minimum amount, meaning the company may sell fewer than all securities and receive significantly less proceeds than the maximum estimated $18.04 million.
• The company has a history of multiple capital raises (September 2024, October 2024, December 2024, February 2025, April 2025), indicating a continuous need for funding and potential for further dilution.

Risks

• Inability to maintain listing of securities on Nasdaq, TSX, or any stock exchange could adversely affect share price and liquidity.
• Investors in this offering will experience immediate and substantial dilution in the book value of their investment.
• Management will have broad discretion over the use of proceeds from this offering and might not apply them in ways that increase investment value.
• The company may seek to raise additional funds or develop strategic relationships by issuing securities that would dilute existing ownership.
• There is no public market for the Warrants and Pre-Funded Warrants being offered, limiting their liquidity.
• Holders of Pre-Funded Warrants and Warrants will have no rights as common shareholders until they acquire common shares upon exercise.
• The Warrants are speculative in nature, and there is no assurance the common share market price will equal or exceed the exercise price.
• A possible short squeeze due to sudden demand exceeding supply may lead to price volatility in common shares.
• The offering may cause the trading price of common shares to decrease due to increased supply.
• The business may be subject to additional regulations in the future, increasing compliance costs.
• Inability to adequately protect intellectual property rights could affect the company's ability to compete.
• The company's status as an emerging growth company and smaller reporting company allows for reduced public disclosure, which may make securities less attractive to some investors.

Future Outlook

BriaCell Therapeutics anticipates completing patient enrollment in its pivotal Phase 3 study for Bria-IMT in late 2025 or early 2026, with top-line data potentially available as early as H1-2026. Positive completion of this study, following FDA review, could lead to full approval and marketing authorization for Bria-IMT in metastatic breast cancer. The company also plans to use its Bria-OTS+ platform in upcoming Phase 1/2a clinical studies for breast and prostate cancer, and BriaPro plans to develop anti-B7-H3 antibodies for multiple cancer indications.

Management Comments

• The pivotal Phase 3 study of Bria-IMT is currently under Fast Track Designation by the U.S. FDA intended to accelerate the review process of novel treatments that address unmet medical needs.
• Positive completion of the pivotal Phase 3 study, following review by FDA, could lead to full approval of the Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.
• BriaCell believes Bria-OTS+ may deliver significant clinical efficacy and survival benefits in breast cancer and prostate cancer, respectively, given its ease of administration, potent, multi-faceted immune system activation, and potentially favorable safety profile.
• The company is excited to collaborate on this important program (Phase 3 study) with authors and BriaCell medical advisory board members Sara A. Hurvitz, MD, Adam M. Brufsky, MD, PhD, and Massimo Cristofanilli, MD.
• The company believes the updated survival data for Bria-IMT shows a meaningful survival advantage in heavily pretreated metastatic breast cancer patient subtypes.

Industry Context

BriaCell Therapeutics operates in the highly competitive and rapidly evolving field of cancer immunotherapy, a sector that harnesses the body's immune system to fight cancer. The company's focus on metastatic breast cancer, particularly in heavily pre-treated and ADC-resistant patients, addresses a critical unmet medical need. The development of personalized, off-the-shelf immunotherapies (Bria-OTS+) and novel antibody therapeutics (anti-B7-H3) positions BriaCell at the forefront of next-generation cancer treatments, aiming to improve upon existing standards of care like ADCs and chemotherapy, which often have limited efficacy in advanced disease settings.

Comparison to Industry Standards

• Bria-IMT regimen's median progression-free survival (PFS) of 3.5 months in heavily pre-treated metastatic breast cancer patients is comparable to or better than that seen in similar studies in patients with fewer prior treatments (median of 4), which reported PFS figures of 1.7 to 2.3 months.
• The median PFS of 4.2 months for patients receiving the Bria-IMT pivotal Phase 3 formulation is approximately twice the PFS figures reported for treatment of physicians choice (TPC) in other similar studies.
• Bria-IMT's clinical benefit rate (CBR) of 56% in evaluable patients appears higher than TPC in other studies (7-10%).
• The median overall survival (OS) of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022) is approximately double that of comparable patients in the literature (5.9-9.8 months).
• In Triple-Negative Breast Cancer (TNBC), Bria-IMT plus CPI showed a median OS of 13.9 months, which is higher than TRODELVY (11.8 months) and significantly higher than single-agent chemotherapy (6.9 months).
• In Hormone Receptor-Positive (HR+) metastatic breast cancer, Bria-IMT plus CPI demonstrated a median OS of 17.3 months, outperforming TRODELVY (14.4 months) and single-agent chemotherapy (11.2 months).
• The 12-month survival rate for Bria-IMT in TNBC patients was 56%, compared to 49% for TRODELVY and 22% for single-agent chemotherapy.
• The 12-month survival rate for Bria-IMT in HR+ patients was 61%, comparable to TRODELVY (61%) and better than single-agent chemotherapy (47%).
• Bria-IMT's favorable tolerability profile, with no interstitial lung disease (ILD) and no treatment-related discontinuations, compares favorably to ADCs which are associated with ILD.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant value appreciation if clinical trials continue to show positive results and lead to market approval, but also face immediate and future dilution from ongoing capital raises and the speculative nature of biotech investments.
• Patients: Direct positive impact through the development of novel immunotherapies for metastatic breast cancer, with promising clinical data suggesting improved survival and response rates, and expanded access policy providing treatment beyond trials.
• Employees: Continued employment and potential growth opportunities within a company making significant clinical advancements in cancer treatment.
• Creditors/Suppliers: Financial stability is supported by capital raises, but ongoing net losses indicate reliance on external funding, which could pose risks if funding becomes difficult to secure.

Next Steps

• Complete patient enrollment in the pivotal Phase 3 study for Bria-IMT in late 2025 or early 2026.
• Report top-line data for the pivotal Phase 3 study as early as H1-2026.
• Continue monitoring data in the CNS metastatic disease subgroup of the Phase 3 study for potential additional market approval indication.
• Continue monitoring ADC resistant patients in the ongoing pivotal Phase 3 study.
• Conduct upcoming Phase 1/2a clinical studies for Bria-OTS+ (specifically Bria-BRES+ and Bria-PROS+).
• Continue GMP manufacturing for Bria-PROS+ to generate clinical supplies.
• Advance development of novel, high affinity anti-B7-H3 antibodies and incorporate them into the Bria-TILsRx platform.
• Continue to provide Bria-IMT to metastatic breast cancer patients through the FDA-authorized Expanded Access Policy.
• Complete the current public offering of common and pre-funded units by September 13, 2025.

Key Dates

Recommendation

Keywords

BriaCell Therapeutics, Immunotherapy, Metastatic Breast Cancer, Bria-IMT, Bria-OTS, Bria-PROS+, Clinical Trials, Phase 3, Phase 1/2, Oncology, Cancer Treatment, SEC Filing, Public Offering, Warrants, Pre-Funded Warrants, Biotechnology, Drug Development, FDA Fast Track, Overall Survival, Progression-Free Survival, Clinical Benefit Rate, CNS Metastasis, ADC Resistant, TNBC, HR+ HER2-, Nasdaq, ThinkEquity